Hls Therapeutics Stock Probability of Future Pink Sheet Price Finishing Over 2.60

HLTRF Stock  USD 2.60  0.17  7.00%   
HLS Therapeutics' future price is the expected price of HLS Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of HLS Therapeutics performance during a given time horizon utilizing its historical volatility. Check out HLS Therapeutics Backtesting, HLS Therapeutics Valuation, HLS Therapeutics Correlation, HLS Therapeutics Hype Analysis, HLS Therapeutics Volatility, HLS Therapeutics History as well as HLS Therapeutics Performance.
  
Please specify HLS Therapeutics' target price for which you would like HLS Therapeutics odds to be computed.

HLS Therapeutics Target Price Odds to finish over 2.60

The tendency of HLS Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 2.60 90 days 2.60 
about 29.83
Based on a normal probability distribution, the odds of HLS Therapeutics to move above the current price in 90 days from now is about 29.83 (This HLS Therapeutics probability density function shows the probability of HLS Pink Sheet to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon HLS Therapeutics has a beta of 0.18. This usually indicates as returns on the market go up, HLS Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding HLS Therapeutics will be expected to be much smaller as well. Additionally HLS Therapeutics has an alpha of 0.2659, implying that it can generate a 0.27 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   HLS Therapeutics Price Density   
       Price  

Predictive Modules for HLS Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as HLS Therapeutics. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.132.606.00
Details
Intrinsic
Valuation
LowRealHigh
0.112.175.57
Details
Naive
Forecast
LowNextHigh
0.052.505.91
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
2.232.502.76
Details

HLS Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. HLS Therapeutics is not an exception. The market had few large corrections towards the HLS Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold HLS Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of HLS Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.27
β
Beta against Dow Jones0.18
σ
Overall volatility
0.17
Ir
Information ratio 0.05

HLS Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of HLS Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for HLS Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
HLS Therapeutics had very high historical volatility over the last 90 days
HLS Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 60.01 M. Net Loss for the year was (13.12 M) with profit before overhead, payroll, taxes, and interest of 50.36 M.
About 64.0% of the company shares are owned by institutional investors

HLS Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of HLS Pink Sheet often depends not only on the future outlook of the current and potential HLS Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. HLS Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding32.5 M

HLS Therapeutics Technical Analysis

HLS Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. HLS Pink Sheet technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of HLS Therapeutics. In general, you should focus on analyzing HLS Pink Sheet price patterns and their correlations with different microeconomic environments and drivers.

HLS Therapeutics Predictive Forecast Models

HLS Therapeutics' time-series forecasting models is one of many HLS Therapeutics' pink sheet analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary HLS Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the pink sheet market movement and maximize returns from investment trading.

Things to note about HLS Therapeutics

Checking the ongoing alerts about HLS Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for HLS Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
HLS Therapeutics had very high historical volatility over the last 90 days
HLS Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the revenue of 60.01 M. Net Loss for the year was (13.12 M) with profit before overhead, payroll, taxes, and interest of 50.36 M.
About 64.0% of the company shares are owned by institutional investors

Other Information on Investing in HLS Pink Sheet

HLS Therapeutics financial ratios help investors to determine whether HLS Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.